2025/04/09 by Federica Giugliano, Elisa Giordano, Laura Gilardi +12 · 1 voice
Medicine · #Neuroendocrine Tumor Research Advances #Lung Cancer Research Studies #Lung Cancer Treatments and Mutations
paper · doi:10.1016/j.ctrv.2025.102940
openalex publication_date 2025/04/09 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/23
Radioligand therapy (RLT) represents a promising advancement in precision oncology and enables the targeted delivery of radiation to cancer cells. This approach has shown success in other tumor types, such as prostate cancer and neuroendocrine tumors. Its potential in metastatic breast cancer (mBC) is currently under investigation. This review discusses RLT mechanism of action, therapeutic potential, and integration into the existing therapeutic landscape of mBC. While clinical trials have shown promising results, challenges remain regarding target heterogeneity, implementation, and optimizing treatment strategies. Further research is essential to integrate RLT into clinical practice and improve patient outcomes fully.